High-Level Changes and Layoffs at FDA Spark Controversy

Apr.02.2025
High-Level Changes and Layoffs at FDA Spark Controversy
FDA mass layoffs and leadership changes: Tobacco regulator Brian King fired, dozens of experts dismissed, sparking controversy and legal battles.

Key Points:

 

FDA Layoffs and Leadership Changes:

The FDA conducted widespread layoffs, removing Brian King, head of the Center for Tobacco Products, and dismissing dozens of experts.

Nearly all senior FDA officials have changed in recent months, mainly through resignations and retirements.

 

Tobacco Regulation Controversy:

Brian King faced criticism for banning fruit- and candy-flavored e-cigarettes, though youth vaping rates have dropped to a 10-year low.

The FDA has rejected millions of flavored e-cigarette applications, leading to multiple lawsuits, one of which has reached the Supreme Court.

 

Challenges for the New Commissioner:

New FDA Commissioner Marty Makary inherits a workforce lacking top experts and must navigate the consequences of the layoffs while shaping tobacco policy.

 

E-Cigarette Industry Reactions:

The Vapor Technology Association welcomed Brian King’s removal, calling it a first step toward correcting FDA’s regulatory missteps.

Tobacco and e-cigarette companies have criticized the FDA for its slow approval process, particularly for low-risk products.

 

Other High-Level Departures:

Several senior officials have recently left or retired, including Deputy Commissioner for Human Foods Jim Jones and Director of the Center for Drug Evaluation and Research Dr. Patrizia Cavazzoni.


According to an April 2 report by the Associated Press, the US Food and Drug Administration (FDA) recently conducted a comprehensive downsizing operation, resulting in the dismissal of tobacco regulation chief Brian King on Tuesday, April 1st. This action has affected top experts in various fields such as food, drugs, vaccines, and nicotine-containing products.

 

Brian King, the head of the FDA Center for Tobacco Products (CTP), wrote in an email to his team,

 

"It is with a heavy heart and profound disappointment that I share I have been placed on administrative leave."

 

Dozens of other employees in FDA’s tobacco center also received notices Tuesday morning that they were being dismissed, including two entire offices responsible for drafting new tobacco regulations and setting policy.

 

The FDA’s former tobacco chief Mitch Zeller said in an interview,

 

"If you make it virtually impossible to create and draft policy, then you are eviscerating the role of the center. From a public health perspective it makes absolutely no sense."

 

Elsewhere at the FDA, the entire press office was also given notice. Senior officials who help oversee new drug reviews and vaccines were also let go, according to FDA staffers who spoke on condition of anonymity because they did not have permission to speak publicly.

 

In 2022, King, who joined the FDA, faced strong criticism from e-cigarette lobbyists for forcing thousands of companies to remove fruit and candy flavored e-cigarettes from the market. During his tenure, the proportion of American teenagers using e-cigarettes has dropped to a new low in 10 years.

 

His removal comes just days after FDA vaccine chief Dr. Peter Marks was forced out, citing Health Secretary Robert F. Kennedy Jr.'s support for vaccine “misinformation and lies” in his resignation letter.

 

This latest change indicates that in recent months, there have been almost complete turnovers in the top leadership of the FDA, responsible for regulating drugs, food, vaccines, medical devices, and tobacco products, mainly through resignations and retirements.

 

Former FDA Commissioner Robert Califf wrote online, “history will see this as a huge mistake.”

 

"The FDA as we’ve known it is finished, with most of the leaders with institutional knowledge and a deep understanding of product development and safety no longer employed," said Califf, who stepped down at the end of the Biden administration.

 

Kennedy is preparing to dismiss 3,500 FDA employees and advance plans to review highly processed foods, children's vaccines, antidepressants, and other longstanding products, all while facing leadership vacancies at the FDA.

 

This wave of resignations signifies that the newly appointed FDA Commissioner, Marty Makary, confirmed last week, will be taking over an agency lacking many top experts and a staff team that has been in turmoil following weeks of layoffs and chaotic rehiring processes. Only a few FDA employees are political appointees, with the majority of the agency's scientific reviews and decisions being overseen by career officials.

 

During the confirmation hearing, Makary told Senate members that he hopes to "evaluate the recent layoffs during the probation period".

 

Both Makary and Kennedy did not elaborate much on how tobacco policy would be integrated into their "Make America Healthy Again" plan. Despite smoking rates being at historic lows, tobacco-related diseases still remain a leading preventable cause of death in the United States, resulting in over 490,000 deaths each year.

 

In recent years, CTP has been under pressure from various critics. Politicians, parents, and anti-tobacco groups are urging the FDA to further crack down on unauthorized e-cigarette products, which may appeal to young people, many of which come from China. Tobacco and e-cigarette companies argue that the FDA is approving new products targeted towards adult smokers (including e-cigarettes) too slowly, with the risks of these products often being much lower than traditional cigarettes.

 

Under King's leadership, the FDA has refused to approve applications for millions of flavored e-cigarettes, citing a lack of data to prove that these products help adult smokers. These rejections have led e-cigarette manufacturers to file multiple lawsuits against the FDA, one of which is scheduled to be heard by the Supreme Court in December 2024.

 

The Vapor Technology Association, which holds a highly critical stance towards Jin's leadership, stated that king's dismissal "is the first step in correcting the broken mindset that has crippled the FDA and the Center for Tobacco Products over the past four years."

 

Other recent departures of FDA leaders include:

 

— Deputy commissioner for foods, Jim Jones, who resigned in February after dozens of his staffers were fired.

— The director of FDA’s drug center, Dr. Patrizia Cavazzoni, who stepped down days before President Donald Trump took office.

— The agency’s second-ranking official, Dr. Namandje Bumpus, who resigned late last year.

— FDA’s longtime medical devices director, Dr. Jeffrey Shuren, who retired last summer.

 

Many deputies and senior scientists have also retired or stepped down in recent weeks.


 

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Brad Rodu Says Declining Cigarette Smoking Is Key to Tobacco Harm Reduction | 2Firsts Interview
Brad Rodu Says Declining Cigarette Smoking Is Key to Tobacco Harm Reduction | 2Firsts Interview
After more than 30 years researching tobacco harm reduction, University of Louisville professor Brad Rodu says opposition to smoke-free alternatives still surprises him. In an exclusive 2Firsts interview in Manila, he argued that declining smoking rates represent progress even if nicotine use rises, discussed nicotine and cancer, and examined Sweden's snus experience and youth vaping. Rodu welcomed recent FDA decisions but criticized slow reviews and poor risk communication. He called a change in the WHO's stance potentially significant, while doubting it would happen soon.
Nov.20
South Korea's Synthetic Nicotine Tax Take Estimated at Just 1.3% of Forecast as Imports Plunge Nearly 97%
South Korea's Synthetic Nicotine Tax Take Estimated at Just 1.3% of Forecast as Imports Plunge Nearly 97%
After synthetic nicotine was placed under tobacco regulation on April 24, 2026, South Korea’s tax collections from synthetic-nicotine vaping products fell far short of government projections. The Chosun Ilbo reported on November 18 that Ministry of Health and Welfare data showed national health promotion charges on synthetic-nicotine liquid e-cigarettes totaled 765 million won from April 24 through September. Using statutory rates, the newspaper estimated combined major taxes and charges at about 2.622 billion won—on a monthly basis roughly 1.3% of an earlier forecast after temporary tax reductions. Customs data showed synthetic-nicotine imports dropped from about 1,467 metric tons in January–April to 45 metric tons in May–August, a nearly 97% decline. Imports of nicotine-analog and nicotine-free liquids totaled 151 metric tons in May–August, exceeding synthetic-nicotine imports in the same period, though both categories were also below January–April volumes.
Regulations
Nov.19
Product | OXVA Introduces XLIM PRO 4 With Liquid-Level Anti-Burn Technology and Dedicated Pods
Product | OXVA Introduces XLIM PRO 4 With Liquid-Level Anti-Burn Technology and Dedicated Pods
Vaping brand OXVA introduced the XLIM PRO 4 refillable pod system in October 2026, featuring Anti-Burn Tech (ABT) based on smart e-liquid-level detection. The system can issue refill alerts and stop power output when e-liquid levels become too low. ABT requires the XLIM PRO 4 device and a dedicated XLIM ABT cartridge. Standard XLIM pods remain compatible but do not support ABT protection. OXVA previously introduced temperature-based anti-burn technology in the XLIM Pro 2 DNA, developed with Evolv. The new device features a 1,800mAh battery, 5–30W output and a 0.98-inch HD color screen. OXVA's official store lists the device at $37.90 and dedicated ABT replacement cartridges at $12.99. Independent testing confirmed the low-liquid protection response but recorded varying cartridge lifespans.
product
Oct.30
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Hungary Moves to End BAT-Backed Tobacco Supply Monopoly Eight Years Early After $200 Million in Profits, With No Compensation Planned
Hungary Moves to End BAT-Backed Tobacco Supply Monopoly Eight Years Early After $200 Million in Profits, With No Compensation Planned
Hungary's government announced on November 18, 2026, plans to terminate the exclusive tobacco retail supply concession held by Országos Dohányboltellátó (ODBE) on June 1, 2027, approximately eight years before the contract's scheduled expiry in 2035. ODBE is owned 49% by a Hungarian subsidiary of British American Tobacco (BAT) and 51% by Tabán Trafik. It has served as the exclusive supplier to Hungary's licensed tobacco retail network since 2015. The proposed legislation would end the concession without compensation and allow other qualified suppliers and tobacco wholesalers to serve retailers directly. ODBE generated HUF 67.3 billion (approximately $200 million) in after-tax profit between 2015 and 2025 and distributed nearly HUF 64 billion ($191 million) in dividends. The bill also proposes changes to retail margins, inventory rules, payment arrangements and procurement penalties, including those affecting heated tobacco products.
company
Nov.19 by 2Firsts Perspectives
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Japan Tobacco Inc. (JT) announced on November 12, 2026, that it had acquired the U.S. assets of nicotine pouch brand CLEW from Nevcore Innovations Inc., including trademarks, intellectual property, product formulations and a Premarket Tobacco Product Application (PMTA). CLEW, currently distributed through selected outlets in 13 U.S. states, will immediately join the JTI LIGGETT portfolio. The transaction follows JT's approximately $2.4 billion acquisition of U.S. cigarette maker Vector Group in 2024. JTI LIGGETT says its existing cigarette brands reach more than 160,000 U.S. retail stores. During the 2026 NACS Show in October, JTI LIGGETT booth staff told 2Firsts that the company had not yet launched nicotine pouches in the United States. Although Nevcore previously announced FDA acceptance of CLEW's PMTA, the brand is absent from the agency's current list of authorized nicotine pouch products. JT has not disclosed a retail expansion plan for CLEW.
Business
Nov.12